Major stock markets outside the United States ended on Friday.
AstraZeneca Plc tumbled 3.6 percent after the European Patent Office revoked a patent on its key asthma drug Symbicort, putting at risk future sales of the blockbuster, which sold $1.02 billion in Europe last year. The FTSEurofirst 300 index of top European shares closed 0.6 percent lower at 1,563.83 points, after rising to as much as 1,575.89 in early trade.